FDA Approves Sobi’s GAMIFANT as the First Treatment for Macrophage Activation Syndrome in Still’s Disease
In a major advancement for rare inflammatory conditions, the FDA has approved GAMIFANT (emapalumab-lzsg) for the treatment of hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in patients with known or suspected Still’s disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease. The approval spans both adult and pediatric populations, including newborns, who show inadequate response or intolerance to glucocorticoids or experience recurrent MAS episodes.
"This approval brings much-needed ...
